Rilotumumab Completed Phase 1 / 2 Trials for Malignant Neoplasm of Stomach / Esophageal Cancers / Esophagogastric Junction Adenocarcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs